

CITATION REPORT

List of articles citing

Bullous rash and brown urine in a systemic lupus erythematosus patient treated with hydroxychloroquine

DOI: 10.1002/art.1780380325

Arthritis and Rheumatism, 1995, 38, 440-3.

Source: <https://exaly.com/paper-pdf/25838946/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
28	Autoimmunity. <i>Current Opinion in Immunology</i> , 1995 , 7, 860-76	7.8	
27	Hepatitis C as another possible cause of porphyria cutanea tarda and systemic lupus erythematosus: comment on the article by Kutz and Bridges. <i>Arthritis and Rheumatism</i> , 1996 , 39, 352-4		7
26	[Porphyria cutanea tarda]. <i>Hautarzt</i> , 1998 , 49, 870-82; quiz 882	1.1	3
25	Porphyria cutanea tarda. <i>Skin Pharmacology and Physiology</i> , 1998 , 11, 321-35	3	9
24	Porphyria cutanea tarda. Don't forget to look at the urine. <i>Postgraduate Medicine</i> , 1999 , 105, 208-10, 213-4	3.7	7
23	Porphyria cutanea tarda affecting a rheumatoid arthritis patient treated with methotrexate: association or coincidence?. <i>Rheumatology</i> , 1999 , 38, 453-6	3.9	4
22	Co-existence of systemic lupus erythematosus and severe hepatic porphyria. <i>Nephrology Dialysis Transplantation</i> , 1999 , 14, 2944-6	4.3	4
21	Questions answered and a \$1 million question raised concerning lupus erythematosus tumidus: is routine laboratory surveillance testing during treatment with hydroxychloroquine for skin disease really necessary. <i>Archives of Dermatology</i> , 2000 , 136, 1044-9		21
20	Increased osteoprotegerin and decreased pyridinoline levels in patients with ankylosing spondylitis: comment on the article by Gratac et al. <i>Arthritis and Rheumatism</i> , 2002 , 46, 3390-1; author reply 3392		3
19	Increased cutaneous reactions to hydroxychloroquine (Plaquenil) possibly associated with formulation change: comment on the letter by Alarc. <i>Arthritis and Rheumatism</i> , 2002 , 46, 3392-6		19
18	The value of rheumatologists to patients with fibromyalgia: comment on the presidential address by Weinblatt. <i>Arthritis and Rheumatism</i> , 2002 , 46, 3390; author reply 3390		3
17	Reply. <i>Arthritis and Rheumatism</i> , 2002 , 46, 3392-3392		0
16	Reply. <i>Arthritis and Rheumatism</i> , 2002 , 46, 3390-3390		4
15	Efficacy of tumor necrosis factor alpha blockade for enthesitis in spondylarthropathy: comment on the article by Marzo-Ortega et al. <i>Arthritis and Rheumatism</i> , 2002 , 46, 3396-8; author reply 3398		
14	Reply. <i>Arthritis and Rheumatism</i> , 2002 , 46, 3398-3398		2
13	Erratum. <i>Arthritis and Rheumatism</i> , 2002 , 46, 3398-3398		
12	Rheumatoid Arthritis and the Skin. <i>Handbook of Systemic Autoimmune Diseases</i> , 2006 , 161-183	0.3	

11	Severe acute hepatitis related to hydroxychloroquine in a woman with mixed connective tissue disease. <i>Clinical Rheumatology</i> , 2007 , 26, 971-2	3.9	39
10	Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 1608-21	5.1	258
9	Chloroquine and hydroxychloroquine. 2016 , 253-267		1
8	The devil\$ in the dosing: severe drug-induced liver injury in a hydroxychloroquine-naive patient with subacute cutaneous lupus erythematosus and porphyria cutanea tarda. <i>Lupus</i> , 2018 , 27, 1383-1386	2.6	9
7	Characterizing the adverse dermatologic effects of hydroxychloroquine: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 563-578	4.5	47
6	Porphyria cutanea tarda. 2000 , 1029-1042		
5	Chloroquine and hydroxychloroquine. 2006 , 722-730		
4	ENDOCRINE AND METABOLIC ADVERSE EFFECTS OF NON-HORMONAL AND NON-METABOLIC DRUGS. 2009 , 571-691		
3	ANTIPROTOZOAL AND ANTIHELMINTHIC DRUGS. 2010 , 777-932		0
2	GLUCOCORTICOIDS AND DISEASE MODIFYING ANTIRHEUMATIC DRUGS. 2010 , 371-667		
1	Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review. <i>Pharmaceuticals</i> , 2022 , 15, 634	5.2	1